Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer based in Pasadena, California, supplies drugs, pharmaceuticals, and hematology-related products to the Department of Veterans Affairs as a prime contractor on GSA Federal Supply Schedule vehicles and related blanket purchase agreements, competing on full-and-open, unrestricted procurement with no set-aside designations.

The vendor operates exclusively as a prime on pharmaceutical supply contracts and holds three recent federal vehicle positions, all issued between February and September 2026. Arrowhead's customer base is concentrated entirely within the Department of Veterans Affairs, split between the Veterans Health Administration's Veterans Integrated Service Network 12 (2 awards, $525 thousand combined potential value) and the National Acquisition Center (1 award, $1.3 million). The National Acquisition Center's blanket purchase agreement carries the larger dollar magnitude despite fewer orders, reflecting the structure of pharmaceutical supply contracting where centralized procurement often yields higher ceilings than regional VISN orders.

The vendor's vehicle footprint centers on the Pharmaceuticals and Drugs schedule (FSS-61-IB), under which it holds a $1.3 million blanket purchase agreement with the National Acquisition Center (effective through September 2027) and a $500 thousand multiple-award Federal Supply Schedule contract with Veterans Integrated Service Network 12 (effective through August 2031). A third contract, a $25 thousand interim agreement under the 42-2A Lifecycle Permanent Stage REDEMPLO procurement vehicle, expired in August 2026. All three awards fall under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals).

Activity is minimal in the source window — three awards in 2026 with combined potential value of $1.8 million — and the vendor has no sub-award footprint or multi-agency customer diversification beyond VA. This is a newly seated pharmaceutical vendor with limited federal exposure relative to major pharmaceutical incumbents on GSA schedules.